We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Vitamin D Levels Tied to COVID-19 Risk for African-Americans

By LabMedica International staff writers
Posted on 29 Mar 2021
Print article
Image: A blood test for Vitamin D showed that African-Americans individuals with low Vitamin D were more at risk from COVID-19 (Photo courtesy of Getty Images)
Image: A blood test for Vitamin D showed that African-Americans individuals with low Vitamin D were more at risk from COVID-19 (Photo courtesy of Getty Images)
Vitamin D has diverse physiological effects, including on calcium regulation, bone density, and immune function. Deficient levels, typically defined as 25-hydroxyvitamin D (also known as calcifediol) level less than 20 ng/mL are common, especially in African-Americans individuals.

Vitamin D is also important for immune function, and a meta-analysis of randomized clinical trials using daily or weekly dosing has found vitamin D supplementation was associated with substantially decreased viral respiratory infections, especially in individuals who were deficient in vitamin D, but also individuals without a deficient level.

A team of Medical Scientists from The University of Chicago (Chicago, IL, USA) examined whether COVID-19 test results are associated with differences in vitamin D levels of 30 ng/mL or greater, including for White individuals and for African-Americans individuals. The team assessed data from 4,638 people tested for COVID-19 from March 3, 2020 to April 10, 2020, who also had data on vitamin D levels within a year prior to COVID-19 testing. COVID-19 status was determined by the Centers for Disease Control and Prevention or Viacor polymerase chain reaction (PCR, Lee's Summit, MO, USA) test used until in-house testing with the Cobas SARS-CoV-2 RT-PCR (Roche Diagnostics, Rotkreuz, Switzerland) began March 15, 2020.

The primary outcome was whether vitamin D level within 14 days was associated with testing positive for COVID-19, and the group controlled for time and vitamin D treatment changes since the vitamin D level was measured, as well as demographic characteristics and comorbidity indicators. The team reported that patients' mean age was around 53 and 69% were women; 49% were African-Americans and 43% were White. They were stratified into four groups by vitamin D levels. African-Americans individuals were more likely than White individuals to have vitamin D levels below 20 ng/mL (36% and 16%, respectively), and more likely to test positive for COVID-19 (9% and 5%, respectively). COVID-19 risk decreased by 5% for each 1 ng/mL increment among individuals with a level of 30 ng/mL or greater in African-Americans individuals.

The authors concluded that COVID-19 risk increased among African-Americans individuals with vitamin D level less than 40 ng/mL compared with those with 40 ng/mL or greater and decreased with increasing levels among individuals with levels greater than 30 ng/mL. No significant associations were noted for White individuals. The study was published on March 19, 2021 in the journal JAMA Network Open.

Related Links:
The University of Chicago
Viacor
Roche Diagnostics


Gold Supplier
Thrombin Generation System
ST Genesia
New
COVID-19 Antigen Test
Instant-view PLUS COVID-19 Antigen Test
New
SARS-CoV-2 Nucleoprotein IgG Antibody ELISA Kit
SARS-CoV-2 Nucleoprotein IgG Antibody ELISA Kit
New
Silver Supplier
Dyspeptic Diagnostic Test
GastroPanel

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.